GBS GLUCOSE BIOSENSOR SYS

Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024

Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on March 6, 2024. INBS will provide an update on the Company’s growth and financial performance in 2023, among other topics.

Spiro Sakiris, INBS’ Chief Financial Officer, is scheduled to present from 3:40 p.m. to 3:50 p.m. Eastern Time on Wednesday, March 6, 2024.

Link to register:

Following the event, an archived webcast will be available on emerginggrowth.com and the Emerging Growth YouTube Channel: . A link to the webcast will be released after the event for convenient access.

Attendees are encouraged to submit their questions in advance to or ask questions throughout the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: 

Company Contact:

Intelligent Bio Solutions Inc.



 | 

Media Contact:

Cheryl Billson

Comma Communications



+44 (0)7791 720460



EN
01/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full ...

Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medi...

 PRESS RELEASE

Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtu...

Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025 NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that its management team will participate in the Sidoti Micro-Cap Virtual Conference being held on August 20-21, 2025. Presentation DetailsDate: Thursday, August 21, 2025Time: 9:15 a.m. Eastern TimeRegistration/Webcast Link: For more information a...

 PRESS RELEASE

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter ...

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering...

 PRESS RELEASE

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leadi...

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS's Intelligent Fingerprinting Drug Screening System will be deployed across a multi-garage bus ne...

 PRESS RELEASE

Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Mi...

Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or prepay the exercise price) certain existing warrants to purchase up to 2...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch